Introduction

Name

• Capromorelin.

Class of drug

• Selective ghrelin receptor agonist.

Description

Chemical name

• 2-amino-N-[2-(3aR-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1R-benzyloxymethyl-2-oxo-ethyl]-isobutyramide L-tartrate.

Molecular formula

• C28H35N5O4·C4H6O6

Molecular weight

• 655.70.

Physical properties

• Oral solution.

Storage requirements

• Store at or below 86°F (30°C).

Uses

Indications

• Inappetence in dogs.

Administration

Precautions

Adverse Reactions

Further Reading

Publications

Refereed papers

• Recent references from PubMed and VetMedResource.
• Rhodes L, Zollers B, Wofford J A et al (2017) Capomorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs. Vet Med Sci 4 (1), 3-16 PubMed.
• Zollers B, Rhodes L & Heinen E (2017) Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study. BMC Vet Res 13 (1), 10 PubMed.
• Zollers B, Wofford J A, Heinen E et al (2016) A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. JVIM 30 (6), 1851-1857 PubMed.
• Zollers B, Rhodes L, Smith R G (2016) Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs. J Vet Pharmacol Ther 40 (2), 140-147 PubMed.
• Zollers B, Huebner M, Armintrout G et al (2016) Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin (ENTYCE®), a novel drug for stimulation of appetite. J Vet Pharmacol Ther 40 (3), 248-255 PubMed.

Other sources of information

• Aratana Therapeutics: www.aratana.com/therapeutics/inappetence; www.aratana.com/wp-content/uploads/2016/05/ENTYCE-Package-Insert.pdf.